Ainos, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Ainos, Inc. granted BioPhoenix Co., Ltd. (Taiwan) a global exclusive license to VELDONA (low-dose oral interferon alpha) for Sjögren's Disease and Thrombocytopenia. Licensee pays $600,000 upfront (due within 15 business days of technology transfer completion), funds all development and regulatory activities, and pays Ainos 25% of net sublicensing revenue. Additional economics include one-time first-sublicense fee (amount redacted) and licensing fees for up to 15 additional indications at redacted per-indication rates capped at redacted aggregate amount. Ainos retains platform ownership, manufacturing rights included in license fee, and 5 years of technical support (8 hours/month free, additional hours at redacted rate).
Why this rating
Small upfront ($600K ≈13.6% of $4.4M market cap) with contingent future revenue. De-risks pharma spend but signals asset monetization, not organic growth. Neutral signal—modest near-term cash inflow against platform relinquishment.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.